Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 14/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.55 |
| ▸ | PDE4A | P27815 | 7/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.52 |
| ▸ | BRD2 | P25440 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595977 | 0.81 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL2930091 | 0.80 | PDE3B (0.63) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7417981 | 0.76 | PDE3B (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10835125 | 0.74 | PDE3B (0.59) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL20889281 | 0.74 | BRD4 (0.60) | PDE3BPDE3ABRD4CREBBPBRD2 | |
| SCHEMBL7420928 | 0.73 | PDE3B (0.49) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7414950 | 0.73 | PDE3B (0.61) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10597216 | 0.73 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11317512 | 0.73 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10596133 | 0.72 | PDE3B (0.61) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | claimed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0247177-A4 | BENZODIAZINONE-PYRIDAZINONE AND HYDROXY-PYRAZOLYL COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES. | RORER INTERNAT OVERSEAS INC (US) | 1988-04-06 | — | — | EP | claimed |
| EP-0247177-A1 | BENZODIAZINONE-PYRIDAZINONE AND HYDROXY-PYRAZOLYL COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1987-12-02 | — | — | EP | claimed |
| WO-1987003201-A1 | BENZODIAZINONE-PYRIDAZINONE AND HYDROXY-PYRAZOLYL COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-06-04 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-20240207279-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| US-11911389-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11878017-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230107723-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230071157-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| EP-4135712-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | Pike Therapeutics, Inc. (CA) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11541002-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11510924-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-11491159-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220347117-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2022-11-03 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220184089-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-11266651-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS INC (CA) | 2021-10-21 | — | — | US | disclosed |
| WO-2021209815-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS, INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3846778-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | Aquestive Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3258958-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210145731-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3811371-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | Aquestive Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-109890366-B | Combination medicine for treating cardiovascular diseases and preparation and use methods thereof | 美进医药公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200397793-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200360340-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3727382-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | Ansella Therapeutics, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10758544-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3692989-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-10668046-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200101009-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-04-02 | — | — | US | disclosed |
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-15 | — | — | US | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | disclosed |
| US-10363299-B2 | Compositions and methods for preventing and treating rhinovirus infections | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2019-07-30 | — | — | US | disclosed |
| EP-2419091-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190183854-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | Ansella Therapeutics, Inc. | 2019-06-20 | — | — | US | disclosed |
| CN-109890366-A | Combination medicine for treating cardiovascular diseases and preparation and use methods thereof | 美进医药公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| CN-109462995-A | The method and composition of bioactivator | 波涛生命科学有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190002984-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2019-01-03 | — | — | US | disclosed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | disclosed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180251840-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180098970-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| WO-2018055211-A1 | NOVEL COMPOUNDS AND METHODS FOR MODULATING UBIQUITINATION | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2018-03-29 | — | — | WO | disclosed |
| EP-3299460-A1 | NOVEL COMPOUNDS AND METHODS FOR MODULATING UBIQUITINATION | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20180043006-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-104546669-B | Nanochannel device and correlation technique | 得克萨斯大学体系董事会 | 2018-01-05 | — | — | CN | disclosed |
| EP-3258958-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | University Of Virginia Patent Foundation (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170319698-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2017-11-09 | — | — | US | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| EP-3212167-A1 | GASTRORETENTIVE GEL FORMULATIONS | Jagotec AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170226585-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2017-08-10 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| EP-3156053-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160376658-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2016-12-29 | — | — | US | disclosed |
| US-9526824-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2307011-B1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2355864-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016134288-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160139161-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2016-05-19 | — | — | US | disclosed |
| WO-2016066256-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-9308162-B2 | Biocompatible oligomer-polymer compositions | TOLMAR THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2015167760-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150246174-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912070-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | Celanese Acetate LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812777-A | Polysaccharide ester microspheres and methods and articles related thereto | CELANESE ACETATE LLC | 2015-07-29 | — | — | CN | disclosed |
| CN-104546669-A | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS | 2015-04-29 | — | — | CN | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9005185-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2291174-B1 | FLOWABLE COMPOSITION COMPRISING BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| CN-102271732-B | Nanochannel devices and related methods | UNIV TEXAS | 2014-12-31 | — | — | CN | disclosed |
| CN-104203220-A | Device and method for sustained release of therapeutic agent | UNIV TEXAS | 2014-12-10 | — | — | CN | disclosed |
| US-20140348936-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140328884-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140315720-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2790677-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790678-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2770984-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140206734-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140180251-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014066463-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140113826-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8697361-B2 | Serotonin transporter gene and treatment of alcoholism | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2014031398-A1 | BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS | TICONA LLC (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140051771-A1 | Biomedical Devices Comprising Molded Polyethylene Components | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140052264-A1 | Porous, Stabilized Craniomaxillofacial Implants and Methods and Kits Relating Thereto | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8632510-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| US-20130240483-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| US-8513304-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013090891-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090893-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-20130131628-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063004-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2255184-B1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | Univ Virginia Patent Found (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| EP-2556830-A1 | Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120302592-A1 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-8314077-B2 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120115149-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2425013-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | University Of Virginia Patent Foundation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-102225046-A | Transdermal drug delivery formulation | NUVO RES INC | 2011-10-26 | — | — | CN | disclosed |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| CN-101296691-B | Transdermal drug delivery dosage form | NUVO RES INC | 2011-07-27 | — | — | CN | disclosed |
| US-7976871-B2 | Modified release composition of highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-07-12 | — | — | US | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20110112159-A1 | SEROTONIN TRANSPORTER GENE AND TREAMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2307011-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| CN-102016571-A | Serotonin transporter gene and treatment of alcoholism | UNIV VIRGINIA | 2011-04-13 | — | — | CN | disclosed |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| EP-2291174-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | Tolmar Therapeutics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2010141470-A2 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-2255184-A2 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | University Of Virginia Patent Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010126603-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| CN-101810592-A | Contain the pharmaceutical preparation that is dispersed in the active matter in the substrate | ALTANA PHARMA AG | 2010-08-25 | — | — | CN | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| CN-101685733-A | High-temperature thermal fuse device | THERM O DISC INC | 2010-03-31 | — | — | CN | disclosed |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-101663028-A | Combined effect of topiramate and ondansetron on alcohol consumption | UNIV VIRGINIA | 2010-03-03 | — | — | CN | disclosed |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090318520-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS DRIVE (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155139-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009148581-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | QLT USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2124909-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | University Of Virginia Patent Foundation (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-100548290-C | Sulfamate derivatives is used for the treatment of the purposes of impulse control disorder | UNIV CINCINNATI (US) | 2009-10-14 | — | — | CN | disclosed |
| WO-2009108837-A2 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009029308-A1 | MEDICATION COMBINATIONS FOR THE TREATMENT OF ALCOHOLISM AND DRUG ADDICTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | disclosed |
| CN-101296691-A | transdermal drug delivery dosage form | NUVO RES INC (CA) | 2008-10-29 | — | — | CN | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008095086-A2 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008077092-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7199151-B2 | DHA-pharmaceutical agent conjugates of taxanes | LUITPOLD PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | disclosed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| EP-1158973-B1 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIV CINCINNATI (US) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1466628-A1 | DHA-pharmaceutical agent conjugates | Luitpold Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | PROTARGA, INC. | 2004-09-16 | — | — | US | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | PROTARGA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6602902-B2 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | PROTARGA, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| CN-1360500-A | Use of sulfamate derivatives for the treatment of impulse control disorders | UNIV CINCINNATI (US) | 2002-07-24 | — | — | CN | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1158973-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | PDE3B 451/4885PDE3A 677/4885PDE4A 1105/4885 |
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | PDE3B 84/4885PDE3A 81/4885PDE4A 49/4885 |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | PGRMC2, PGRMC1, CYP3A43 | PDE3B 649/4885PDE3A 354/4885PDE4A 477/4885 |
| US-20180043006-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | CD4, HLA-DRB1, CD74 | PDE3B 4631/4885PDE3A 4705/4885PDE4A 4142/4885 |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | BMP2, CHERP, PUF60 | PDE3B 452/4885PDE3A 348/4885PDE4A 1493/4885 |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | PDE3B 881/4885PDE3A 961/4885PDE4A 645/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | PDE3B 451/4885PDE3A 677/4885PDE4A 1105/4885 |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | PDE3B 881/4885PDE3A 961/4885PDE4A 645/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | PDE3B 2617/4885PDE3A 2123/4885PDE4A 1506/4885 |
| US-20230107723-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE3B 84/4885PDE3A 81/4885PDE4A 49/4885 |
| US-20180251840-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | PDE3B 587/4885PDE3A 723/4885PDE4A 459/4885 |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE3B 84/4885PDE3A 81/4885PDE4A 49/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | PDE3B 881/4885PDE3A 961/4885PDE4A 645/4885 |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | SLC6A3, SLC6A4, ADH5 | PDE3B 550/4885PDE3A 428/4885PDE4A 486/4885 |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | ADRA2C, ADRB3, ADRA2B | PDE3B 28/4885PDE3A 31/4885PDE4A 94/4885 |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | PDE3B 587/4885PDE3A 723/4885PDE4A 459/4885 |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | PDE3B 872/4885PDE3A 654/4885PDE4A 2183/4885 |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | SLC6A3, SLC6A4, HTR5A | PDE3B 492/4885PDE3A 314/4885PDE4A 432/4885 |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | PDE3B 8/4885PDE3A 9/4885PDE4A 113/4885 |
| US-20140206734-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | PDE3B 587/4885PDE3A 723/4885PDE4A 459/4885 |
| US-20190183854-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | PDE3B 1086/4885PDE3A 638/4885PDE4A 2567/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE3B 55/4885PDE3A 49/4885PDE4A 106/4885 |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | PDE3B 881/4885PDE3A 961/4885PDE4A 645/4885 |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | PDE3B 1086/4885PDE3A 638/4885PDE4A 2567/4885 |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | OPRL1, OPRM1, HTR2A | PDE3B 1444/4885PDE3A 1123/4885PDE4A 1456/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | PDE3B 3179/4885PDE3A 2972/4885PDE4A 1463/4885 |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | PDE3B 881/4885PDE3A 961/4885PDE4A 645/4885 |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | ALOX12, FABP2, ALOX15B | PDE3B 3259/4885PDE3A 3832/4885PDE4A 2509/4885 |
| US-20170226585-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | PDE3B 587/4885PDE3A 723/4885PDE4A 459/4885 |
| US-20110112159-A1 | SEROTONIN TRANSPORTER GENE AND TREAMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | PDE3B 1266/4885PDE3A 1087/4885PDE4A 405/4885 |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | SLC6A3, SLC6A4, SLC6A2 | PDE3B 2295/4885PDE3A 1901/4885PDE4A 1605/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | PDE3B 3032/4885PDE3A 1584/4885PDE4A 3267/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | PDE3B 174/4885PDE3A 190/4885PDE4A 336/4885 |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | SMURF1, SMURF2, SMS | PDE3B 918/4885PDE3A 689/4885PDE4A 1320/4885 |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | PDE3B 15/4885PDE3A 18/4885PDE4A 2/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | PDE3B 174/4885PDE3A 190/4885PDE4A 336/4885 |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | PDE3B 23/4885PDE3A 40/4885PDE4A 20/4885 |
| US-20190002984-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | PDE3B 587/4885PDE3A 723/4885PDE4A 459/4885 |
| US-11510924-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | PDE3B 84/4885PDE3A 81/4885PDE4A 49/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | PDE3B 427/4885PDE3A 273/4885PDE4A 1323/4885 |
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | PDE3B 2708/4885PDE3A 2606/4885PDE4A 2120/4885 |
| US-10363299-B2 | Compositions and methods for preventing and treating rhinovirus infections | CD4, HLA-DRB1, CD74 | PDE3B 4631/4885PDE3A 4705/4885PDE4A 4142/4885 |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | PDE3B 3179/4885PDE3A 2972/4885PDE4A 1463/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | PDE3B 1379/4885PDE3A 1616/4885PDE4A 4012/4885 |
| US-10668046-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | PDE3B 1086/4885PDE3A 638/4885PDE4A 2567/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | PDE3B 881/4885PDE3A 961/4885PDE4A 645/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | PDE3B 21/4885PDE3A 32/4885PDE4A 10/4885 |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | SMURF1, SGMS1, SMURF2 | PDE3B 904/4885PDE3A 830/4885PDE4A 946/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | PDE3B 2016/4885PDE3A 1812/4885PDE4A 3283/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE3B 84/4885PDE3A 81/4885PDE4A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.